Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006916. doi: 10.1212/WNL.0000000000006916. [Epub ahead of print]

PMID:
30635477
2.

Tools to address health care delivery challenges and improve patient outcomes.

Corboy JR.

Neurol Clin Pract. 2018 Dec;8(6):463. doi: 10.1212/CPJ.0000000000000565. No abstract available.

PMID:
30588371
3.

Strength in numbers.

Corboy JR.

Neurol Clin Pract. 2018 Oct;8(5):363. doi: 10.1212/CPJ.0000000000000541. No abstract available.

PMID:
30564476
4.

Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis.

Gould JR, Reineberg AE, Cleland BT, Knoblauch KE, Clinton GK, Banich MT, Corboy JR, Enoka RM.

Front Physiol. 2018 Oct 17;9:1404. doi: 10.3389/fphys.2018.01404. eCollection 2018.

5.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

6.

Real-world practice.

Corboy JR.

Neurol Clin Pract. 2018 Aug;8(4):275. doi: 10.1212/CPJ.0000000000000501. No abstract available.

PMID:
30140570
7.

Curbside consults join the telemedicine era.

Nuwer MR, Corboy JR.

Neurol Clin Pract. 2018 Jun;8(3):177-178. doi: 10.1212/CPJ.0000000000000459. No abstract available.

PMID:
30105154
8.

Providing patient-centered care in the digital era.

Corboy JR.

Neurol Clin Pract. 2018 Jun;8(3):171. doi: 10.1212/CPJ.0000000000000474. No abstract available.

PMID:
30105147
9.

The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.

Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E.

J Neurol Sci. 2018 Jul 15;390:89-93. doi: 10.1016/j.jns.2018.04.021. Epub 2018 Apr 13.

PMID:
29801915
10.

Partners in enhancing functional ability and well-being.

Corboy JR.

Neurol Clin Pract. 2018 Apr;8(2):83. doi: 10.1212/CPJ.0000000000000447. No abstract available.

PMID:
29708226
11.

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.

Corboy JR, Weinshenker BG, Wingerchuk DM.

Neurology. 2018 Jun 12;90(24):1106-1112. doi: 10.1212/WNL.0000000000005574. Epub 2018 Apr 23. Review.

PMID:
29685920
12.

The physician as captain of the patient-centered ship.

Corboy JR.

Neurol Clin Pract. 2018 Feb;8(1):1. doi: 10.1212/CPJ.0000000000000427. No abstract available.

PMID:
29517064
13.

Message from the Editors to our Reviewers.

Corboy JR, Powers LB, Anderson DC, Barbano RL.

Neurol Clin Pract. 2018 Feb;8(1):2-3. doi: 10.1212/CPJ.0000000000000428. No abstract available.

PMID:
29517054
14.

Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.

Hassani A, Corboy JR, Al-Salam S, Khan G.

PLoS One. 2018 Feb 2;13(2):e0192109. doi: 10.1371/journal.pone.0192109. eCollection 2018.

15.

Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).

Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M.

Neurology. 2018 Feb 27;90(9):e797-e807. doi: 10.1212/WNL.0000000000005013. Epub 2018 Jan 31.

PMID:
29386274
16.

The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Solomon AJ, Corboy JR.

Nat Rev Neurol. 2017 Sep;13(9):567-572. doi: 10.1038/nrneurol.2017.106. Epub 2017 Aug 11. Review. No abstract available.

PMID:
28799551
17.

Message from the Editors to our Reviewers.

Gross RA, Worrall BB, Amato AA, Cascino GD, Ciccarelli O, Corboy JR, Dalmau JO, Gottesman RF, Grossman M, Millichap JJ, Mink JW, Pulst SM, Uitti RJ.

Neurology. 2017 Jul 4;89(1):2-10. doi: 10.1212/WNL.0000000000004104. No abstract available.

PMID:
28674154
18.

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary.

Corboy JR.

Mult Scler. 2017 Aug;23(9):1192-1193. doi: 10.1177/1352458517717809. Epub 2017 Jul 4. No abstract available.

PMID:
28673113
19.

Baló concentric sclerosis evolving from apparent tumefactive demyelination.

Hardy TA, Corboy JR, Weinshenker BG.

Neurology. 2017 May 30;88(22):2150-2152. doi: 10.1212/WNL.0000000000003990. Epub 2017 May 3. No abstract available. Erratum in: Neurology. 2017 Jul 25;89(4):411.

PMID:
28468846
20.

Reducing costs while enhancing quality of care in MS.

Kister I, Corboy JR.

Neurology. 2016 Oct 11;87(15):1617-1622. Epub 2016 Sep 2.

21.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

22.

Multiple sclerosis prevalence in the United States commercially insured population.

Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD.

Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.

23.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

PMID:
26621682
24.

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.

Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29.

25.

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics.

Solomon AJ, Klein EP, Corboy JR, Bernat JL.

Mult Scler. 2015 Oct;21(12):1593-9. doi: 10.1177/1352458515569101. Epub 2015 Feb 25.

PMID:
25716879
26.

The effects of test-enhanced learning on long-term retention in AAN annual meeting courses.

Larsen DP, Butler AC, Aung WY, Corboy JR, Friedman DI, Sperling MR.

Neurology. 2015 Feb 17;84(7):748-54. doi: 10.1212/WNL.0000000000001264. Epub 2015 Jan 21.

27.
28.

Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.

Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr.

J Neuroimmunol. 2014 May 15;270(1-2):75-85. doi: 10.1016/j.jneuroim.2014.03.009. Epub 2014 Mar 15.

29.

Manipulating the nervous system: The brave new world.

Corboy JR.

Neurol Clin Pract. 2013 Dec;3(6):455-456. doi: 10.1212/01.CPJ.0000435750.40492.09. No abstract available.

30.

The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study.

Lafosse JM, Mitchell SM, Corboy JR, Filley CM.

J Int Neuropsychol Soc. 2013 Oct;19(9):995-1008. doi: 10.1017/S1355617713000957.

PMID:
24059259
31.

The American Academy of Neurology's top five Choosing Wisely recommendations.

Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS.

Neurology. 2013 Sep 10;81(11):1022-3. doi: 10.1212/WNL.0b013e3182a69c98. No abstract available.

PMID:
24019388
32.

Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.

Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.

Am J Manag Care. 2013 Apr;19(4):278-85.

33.

The revolution of practice.

Corboy JR.

Neurol Clin Pract. 2013 Apr;3(2):87. doi: 10.1212/CPJ.0b013e31828e17fe. No abstract available.

34.

The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration.

Hebert JR, Corboy JR.

Gait Posture. 2013 May;38(1):37-42. doi: 10.1016/j.gaitpost.2012.10.015. Epub 2012 Nov 28.

PMID:
23200463
35.

Annual checkup.

Corboy JR.

Neurol Clin Pract. 2012 Dec;2(4):263-264. doi: 10.1212/CPJ.0b013e318278f3a2. No abstract available.

36.

Practice across borders.

Corboy JR.

Neurol Clin Pract. 2012 Sep;2(3):169-170. doi: 10.1212/CPJ.0b013e31826af286. No abstract available.

37.

Broadening our vision.

Corboy JR.

Neurol Clin Pract. 2012 Jun;2(2):89-90. doi: 10.1212/CPJ.0b013e31825adc6c. No abstract available.

38.

Call for submissions!

Corboy JR.

Neurol Clin Pract. 2012 Mar;2(1):1-2. doi: 10.1212/CPJ.0b013e31824cb0cd. No abstract available.

39.

Breaking clinical ground.

Corboy JR.

Neurol Clin Pract. 2011 Dec;1(1):1. doi: 10.1212/CPJ.0b013e31823d07e3. No abstract available.

40.

Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial.

Hebert JR, Corboy JR, Manago MM, Schenkman M.

Phys Ther. 2011 Aug;91(8):1166-83. doi: 10.2522/ptj.20100399. Epub 2011 Jun 16.

PMID:
21680771
41.

Results of the American Academy of Neurology resident survey.

Freeman WD, Nolte CM, Matthews BR, Coleman M, Corboy JR.

Neurology. 2011 Mar 29;76(13):e61-7. doi: 10.1212/WNL.0b013e318212a871.

PMID:
21444895
42.

Therapeutic options in multiple sclerosis: five new things.

Miravalle A, Corboy JR.

Neurology. 2010 Nov 2;75(18 Suppl 1):S22-7. doi: 10.1212/WNL.0b013e3181fb3676. Review. No abstract available.

PMID:
21041767
43.

Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature.

Haug A, Mahalingam R, Cohrs RJ, Schmid DS, Corboy JR, Gilden D.

J Neurol Sci. 2010 May 15;292(1-2):85-8. doi: 10.1016/j.jns.2010.01.019. Epub 2010 Feb 19. Review.

44.

Emerging therapies for treatment of multiple sclerosis.

Corboy JR, Miravalle AA.

J Inflamm Res. 2010;3:53-9. Epub 2010 Jul 23.

45.

How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis.

Butler MA, Corboy JR, Filley CM.

Neuropsychol Rev. 2009 Sep;19(3):399-410. doi: 10.1007/s11065-009-9089-y. Epub 2009 Apr 17. Review.

PMID:
19373561
46.

Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder.

Kleinschmidt-Demasters BK, Cummings TJ, Hulette CM, Morgenlander JC, Corboy JR.

J Neuropathol Exp Neurol. 2009 Apr;68(4):432-9. doi: 10.1097/NEN.0b013e31819fd897.

PMID:
19287308
47.

Education research: neurology residency training in the new millennium.

Schuh LA, Adair JC, Drogan O, Kissela BM, Morgenlander JC, Corboy JR.

Neurology. 2009 Jan 27;72(4):e15-20. doi: 10.1212/01.wnl.0000342389.60811.ca.

PMID:
19171823
48.

Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.

Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF.

Clin Breast Cancer. 2008 Oct;8(5):449-52. doi: 10.3816/CBC.2008.n.055.

PMID:
18952560
49.

Maintenance of certification: ready or not, here it comes.

Corboy JR, Elkind MS.

Neurology. 2008 Aug 19;71(8):544-5. doi: 10.1212/01.wnl.0000323935.26470.c3. No abstract available.

PMID:
18711107
50.

The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic.

Brousseau KM, Arciniegas DB, Carmosino MJ, Corboy JR.

Mult Scler. 2007 Jul;13(6):749-53. Epub 2007 Mar 15.

PMID:
17613603

Supplemental Content

Loading ...
Support Center